As GLP-1 weight-loss drugs such as Wegovy, Zepbound and Mounjaro become more widely used, consumer health companies face a fundamental market shift.

This white paper examines how obesity medicines are changing demand across consumer health categories, highlighting where growth opportunities are likely to emerge and which categories may face pressure. It explores the implications for nutrition, protein supplementation, gastrointestinal support, hydration, micronutrients, pharmacy services and consumer health innovation as obesity becomes an increasingly manageable chronic condition.